在向农村记忆诊所介绍时,抗胆固醇药物的使用是否会在一年内预测认知或功能下降?
Devin Proulx1, Andrew Kirk2, Megan O'Connell3
1College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
之前使用抗胆固醇药物可能会对阿尔茨海默病 (AD) 患者的认知和功能结果产生负面影响,即使在药物停止后也是如此. 这表明在给老年人开这些药物时需要谨慎.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 抗胆固醇药物与认知能力下降有关,特别是在痴呆症患者中.
- 评估先前抗胆固醇药物对痴呆症预后的长期影响至关重要.
研究的目的:
- 为了比较认知和功能评分在1年的随访在记忆诊所的患者之前的抗胆固醇暴露与那些没有.
- 为了确定以前使用抗胆固醇药是否会影响停药后痴呆症预后.
主要方法:
- 在578名患有各种类型痴呆症的患者,包括阿尔茨海默病 (AD) 的长度研究.
- 将服用抗胆固醇药的患者与在基线不服用抗胆固醇药的患者进行了比较;所有抗胆固醇药都被停止服用.
- 在基线和1年的随访中使用了迷你心理状态检查 (MMSE) 和功能活动问卷 (FAQ).
主要成果:
- 整体MMSE或FAQ分数或它们在不同组之间的变化没有显著差异.
- 对AD患者的亚组分析显示,初始MMSE和后续FAQ得分存在显著差异.
- 之前使用抗胆固醇药物的AD患者在统计学上具有相似的随访MMSE,但随访FAQ得分明显较差.
结论:
- 以前服用抗胆固醇药物的阿尔茨海默病患者可能会出现更严重的认知和功能衰退.
- 研究结果表明,抗胆固醇药物暴露对AD预后的潜在长期负面影响.
- 在老年人中使用抗胆固醇药物需要仔细考虑,因为可能会产生持久的影响.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
相关概念视频
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
